Pembrolizumab vs Rituximab
Pembrolizumab vs Rituximab: Overview
This comparison examines the pharmacological differences between Pembrolizumab and Rituximab.
Mechanism of Action
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Rituximab: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.
Pharmacokinetics
Half-life: Pembrolizumab — 26 days; Rituximab — 22 days.
Chemical Properties
Type: Pembrolizumab — Antibody; Rituximab — Antibody.